(888) 552-6760 SCHEDULE AN APPOINTMENT

Parastou Tizro,

M.D.

Pathologist

Biography photo
Location
City of Hope Chicago
2520 Elisha Avenue
Zion, IL 60099
Specialties
Pathology
Education
Medical school:
Degrees
  • 2009, Doctor of Medicine, Tabriz University of Medical Sciences, School of Medicine, Tabriz, Iran
Fellowship
  • 2024, Molecular Genetic, Cedars-Sinai Medical Center, Los Angeles, California
  • 2022, Hematopathology, City of Hope Comprehensive Cancer Center, Duarte, California
Residency
  • 2021, Pathology, George Washington University, Washington, D.C.
Professional Experience
  • 2024-Present, Assistant Clinical Professor, Department of Pathology, City of Hope, Duarte, California
Academic Appointments
  • Assistant Clinical Professor, Department of Pathology
About Me

Parastou Tizro, M.D., is a hematopathologist at City of Hope® Cancer Center Duarte, where she provides accurate and rapid diagnoses for patients with blood disorders and lymphomas, helping them receive the most targeted, effective cancer treatment plans possible.

Dr. Tizro earned her medical degree at Tabriz University of Medical Sciences in Iran. She then completed a residency in pathology at George Washington University in Washington, D.C., followed by a two-year hematopathology fellowship at City of Hope and advanced training in molecular genetics at Cedars-Sinai Medical Center in Los Angeles.

In addition to her clinical work, Dr. Tizro has published more than a dozen papers in peer-reviewed journals and two book chapters. During her residency, she was recognized as resident of the year two years running and honored as Best Researcher of the Year.

Dr. Tizro’s takes a collaborative, respectful approach to working with her patients, unraveling complex diagnostic puzzles to make a difference in their cancer journeys.

Patient ratings
Star ratings and comments are only available for medical, radiation and gynecologic oncologists. Gynecologic surgical offerings are not included at this time due to a different survey tool required to evaluate these services. CTCA uses a validated Press Ganey® survey, which captures patient experience feedback for the primary oncology services of chemotherapy and radiation therapy at our comprehensive care and research centers. Following industry best practice, star ratings and comments are only published for physicians with a minimum of 30 completed patient surveys.